Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Bone Marrow Transplant ; 56(7): 1493-1508, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34031556

RESUMO

Coronavirus disease-19 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), represents one of the biggest challenges of 21st century, threatening public health around the globe. Increasing age and presence of co-morbidities are reported risk factors for severe disease and mortality, along with autoimmune diseases (ADs) and immunosuppressive treatments such as haematopoietic stem cell transplantation (HSCT), which are also associated with adverse outcomes. We review the impact of the pandemic on specific groups of patients with neurological, rheumatological, and gastroenterological indications, along with the challenges delivering HSCT in adult and pediatric populations. Moving forward, we developed consensus-based guidelines and recommendations for best practice and quality of patient care in order to support clinicians, scientists, and their multidisciplinary teams, as well as patients and their carers. These guidelines aim to support national and international organizations related to autoimmune diseases and local clinical teams delivering HSCT. Areas of unmet need and future research questions are also highlighted. The waves of the COVID-19 pandemic are predicted to be followed by an "endemic" phase and therefore an ongoing risk within a "new normality". These recommendations reflect currently available evidence, coupled with expert opinion, and will be revised according to necessary modifications in practice.


Assuntos
Doenças Autoimunes , COVID-19 , Transplante de Células-Tronco Hematopoéticas , Adulto , Doenças Autoimunes/terapia , Criança , Humanos , Pandemias , SARS-CoV-2
2.
Clin J Oncol Nurs ; 16 Suppl: 23-35, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22641282

RESUMO

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid malignancies with variability in clinical presentation, disease trajectory, treatment goals, and expected outcomes. The treatment of patients with MDS, therefore, often differs from patient to patient. Tools are needed to aid effective communication with patients, their caregivers, and their dedicated team of healthcare professionals. The use of methods often employed in clinical trials can help healthcare providers diagnose and classify risk status, track trends within patient responses, manage adverse events, set treatment expectations, and provide ongoing supportive care. This article discusses several tools and strategies available for the management of patients with MDS throughout the continuum of their disease.


Assuntos
Síndromes Mielodisplásicas/tratamento farmacológico , Enfermagem Oncológica/métodos , Planejamento de Assistência ao Paciente , Idoso , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Gerenciamento Clínico , Humanos , Imunossupressores/uso terapêutico , Masculino , Síndromes Mielodisplásicas/diagnóstico , Síndromes Mielodisplásicas/enfermagem , Prognóstico , Medição de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA